Top Markets
#1 Islamic Coin Islamic Coin +151.47%
#2 DOVU DOVU +48.81%
#3 Black Phoenix Black Phoenix +34.68%
#4 Velvet Velvet +29.04%
#5 Cross Cross +22.45%
#6 Akedo Akedo +17.41%
#7 DoubleZero DoubleZero +14.34%
#8 Not in Employment, Education, or Training Not in Employment, Education, or Training +11.22%
#9 Cap Cap +10.26%
#10 Fake World Assets Fake World Assets +10.23%
Coin of the day
Islamic Coin Islamic Coin
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
InVivo Therapeutics Holdings Corporation InVivo Therapeutics Holdings Corporation

InVivo Therapeutics Holdings Corporation

NVIV
Kedudukan dalam Saham #39769
InVivo Therapeutics Holdings Corp. is a biotechnology and biomaterials firm,... InVivo Therapeutics Holdings Corp. is a biotechnology and biomaterials firm, actively involved in research and clinical development. The company specializes in creating and bringing to market innovative biopolymer scaffolding devices designed to address spinal cord injuries (SCI). Its primary investigational product is the Neuro-Spinal Scaffold implant, a bioresorbable polymer scaffold. This device is engineered to be implanted directly at the site of injury within the spinal cord, aiming to treat acute SCI. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Harga Saham
$0.26
Disegerakkan terakhir: 2024-03-11
Modal Pasaran
$356.29K
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan InVivo Therapeutics Holdings Corporation (NVIV)

Kategori

Healthcare
Pendapatan untuk InVivo Therapeutics Holdings Corporation (NVIV)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini InVivo Therapeutics Holdings Corporation, pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi InVivo Therapeutics Holdings Corporation dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE